{"id":991455,"date":"2026-08-06T13:47:12","date_gmt":"2026-08-06T17:47:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-inc-receives-notice-of-allowance-for-new-u-s-patent-covering-exosome-based-immunotherapy-for-type-1-diabetes-deepening-ip-protection-across-its-myelocelz\/"},"modified":"2026-08-06T13:47:12","modified_gmt":"2026-08-06T17:47:12","slug":"creative-medical-technology-holdings-inc-receives-notice-of-allowance-for-new-u-s-patent-covering-exosome-based-immunotherapy-for-type-1-diabetes-deepening-ip-protection-across-its-myelocelz","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-inc-receives-notice-of-allowance-for-new-u-s-patent-covering-exosome-based-immunotherapy-for-type-1-diabetes-deepening-ip-protection-across-its-myelocelz\/","title":{"rendered":"Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz\u2122, CELZ-101 and CELZ-201 Diabetes Platforms"},"content":{"rendered":"

\nNewly Allowed Patent Protects Cell-Free MyeloCelz\u2122 Exosome Technology Designed to Suppress Autoimmune Destruction of Insulin-Producing Cells, Reinforcing Creative Medical’s Multi-Program Diabetes Strategy
\n<\/h2>\n
\n

PHOENIX, Aug. 06, 2026 (GLOBE NEWSWIRE) — Creative Medical Technology Holdings, Inc.<\/strong> (NASDAQ: CELZ) (\u201cCreative Medical\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled \u201cSuppression of Diabetes Using Exosomes From Stem Cell Programmed Myeloid Cells<\/em>\u201d (U.S. Application No. 17\/931,868).<\/p>\n

Once formally issued, the patent will extend Creative Medical\u2019s intellectual property protection around its proprietary MyeloCelz\u2122 platform, a cell-free exosome technology derived from stem-cell-programmed myeloid cells that is designed to induce antigen-specific immune tolerance and suppress the autoimmune destruction of insulin-producing pancreatic beta cells that underlies Type 1 diabetes (T1D). The allowed claims cover the use of these exosomes alone, or in combination with other tolerance-promoting agents such as antibodies, cellular therapies and small molecules, to selectively shut down the immune cells responsible for attacking the pancreas while preserving the immune system\u2019s ability to fight infection and disease.<\/p>\n

\n Strengthening a Multi-Layered Patent Estate Around Creative Medical’s Diabetes Franchise<\/strong>\n <\/p>\n

This Notice of Allowance is the latest in a series of USPTO actions strengthening Creative Medical\u2019s intellectual property position across its immunology and endocrinology pipeline. It follows the Company\u2019s prior Notices of Allowance covering \u201cPrevention and\/or Treatment of Type 1 Diabetes by Augmentation of Myeloid Suppressor Cell Activity\u201d and \u201cTreatment of Heart Failure and\/or Post Infarct Pathological Remodeling by Ex Vivo Reprogrammed Immune Cells,\u201d both of which were subsequently issued as U.S. Patent Nos. 12,931,925 and 12,385,011, respectively, providing protection into 2042 and 2043.<\/p>\n

The newly allowed exosome patent directly complements the Company\u2019s broader diabetes portfolio, which spans multiple stages of disease and mechanisms of action: CELZ-201 (olastrocel\/AlloStem\u00ae<\/sup>)<\/strong>, currently being evaluated in the FDA-cleared CREATE-1 trial for newly diagnosed T1D; CELZ-101 (etaroleucel\/ImmCelz\u00ae<\/sup>)<\/strong>, which holds FDA Orphan Drug Designation for use alongside pancreatic islet transplantation in brittle T1D; and CELZ-001<\/strong>, the Company\u2019s program for late-stage Type 2 diabetes. Creative Medical\u2019s overall intellectual property estate now comprises approximately 60 issued patents and pending applications, with seven issued U.S. patents and 39 pending U.S. applications on file with the USPTO.<\/p>\n

\u201cEach new Notice of Allowance adds another layer of protection around the core biology that differentiates our platform,\u201d said Timothy Warbington, President and CEO of Creative Medical Technology Holdings<\/strong>. \u201cThis exosome-based approach gives us a cell-free way to pursue the same antigen-specific tolerance mechanism we are already advancing clinically with CELZ-101 and CELZ-201. Building overlapping IP protection across both our cellular and cell-free diabetes programs is a deliberate strategy to maximize the long-term value of our platform for patients and shareholders alike.\u201d<\/p>\n

\n A Large and Growing Market Opportunity in Type 1 Diabetes<\/strong>\n <\/p>\n

Type 1 diabetes remains a lifelong autoimmune condition with no approved cure. According to the U.S. Centers for Disease Control and Prevention, approximately 2.1 million Americans, including 1.8 million adults and 314,000 children and adolescents, are living with diagnosed T1D. Independent market research estimates the global Type 1 diabetes market at roughly $18 billion in 2026, with continued double-digit growth expected over the next several years as cell- and immune-based approaches advance through clinical development. Current standard-of-care treatment remains centered on exogenous insulin replacement and non-specific immunosuppression, underscoring the unmet need for therapies, like Creative Medical\u2019s pipeline, aimed at inducing durable, antigen-specific immune tolerance.<\/p>\n

\n What Comes Next<\/strong>\n <\/p>\n

Following receipt of this Notice of Allowance, Creative Medical plans to:<\/p>\n